Statins for the treatment of COVID-19 patients: an updated meta-analysis of randomized controlled trials

期刊论文
出版模式：

开放获取
发表日期：

2024年10月15日

查看全文

Fatemeh Movahed,
Ehsan Heidari,
Masoud Dehbozorgi,
Saba Goodarzi,
Fatemeh Esmaeilpur Abianeh,
Mohammad Abbasi,
Aida Rezaei Nejad,
Mohammad Javad Amini,
Mahmood Bakhtiyari,
Mojtaba Hedayat Yaghoubi,
Arman Shafiee

摘要

Background

Statin is a low-cost and easily accessible therapeutic option for COVID-19 patients. Previous observational studies and meta-analyses suggest using statins for COVID-19 patients.

Methods

Databases including Medline, Scopus, Embase, Cochrane Library, and clinicaltrials.gov were systematically searched.

Results

After screening 754 records, 9 trials were included. Overall, the study demonstrated a non-significant reduction in all-cause mortality (p = 0.14, RR 0.90, 95% CI 0.79–1.03), no significant difference in the need for mechanical ventilation (p = 0.62, RR 0.95, 95% CI 0.77–1.17), and a non-significant reduction in length of hospitalization (p = 0.71, MD − 0.17 (95% CI − 1.09, 0.76)). The certainty of evidence varied across outcomes, with most demonstrating reasonable certainty.

Conclusion

Our study did not support clinical efficacy of statins for the treatment of COVID-19.